Vaxxa AbNGM: VAXXA

VAXXA: Insolvency segment up 30% over Q1, with short-term losses from expansion investments

· Issued by Vaxxa AB

Revenue and earnings declined year-over-year due to major investments in expansion, but the insolvency segment grew 30% over Q1. Margins are expected to improve as new capacity becomes operational.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Vaxxa Ab

All Vaxxa Ab news releases